Retatrutide: The Complete Guide to the Triple Agonist
Retatrutide is the most potent weight loss peptide ever tested in clinical trials. The world's first triple hormone receptor agonist — targeting GLP-1, GIP, and glucagon simultaneously — delivered an average of 28.7% body weight lost (71.2 lbs) in its first Phase 3 trial. It is not yet FDA-approved and cannot be prescribed.
Retatrutide is not FDA-approved and cannot be prescribed.
It is only available through clinical trial enrollment. The information on this page is for educational purposes only — consult a healthcare provider for treatment options.
Key Facts at a Glance
- Drug class
- Triple GIP/GLP-1/Glucagon receptor agonist
- Administration
- Once-weekly subcutaneous injection
- FDA approval
- Not yet approved — Phase 3 trials
- Average loss
- 28.7% body weight (68 wks, TRIUMPH-4)
- Manufacturer
- Eli Lilly
- Expected filing
- Potentially 2027 (pending remaining trials)
- Trial doses
- 1 mg, 4 mg, 8 mg, 9 mg, 12 mg
- Brand name
- None yet (investigational)
Table of Contents
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It activates three incretin and metabolic hormone receptors simultaneously:
- GLP-1Appetite suppression, gastric slowing (shared with semaglutide and tirzepatide)
- GIPEnhanced insulin response, metabolic regulation (shared with tirzepatide)
- GlucagonPromotes fat burning, increases energy expenditure (unique to retatrutide)
No other approved or late-stage medication targets all three pathways. This triple mechanism is why retatrutide has produced more weight loss than semaglutide or tirzepatide in their respective trials. For a deeper look at currently available options, see our tirzepatide vs. semaglutide comparison.
How Does Retatrutide Work?
Retatrutide combines and extends the mechanisms of its predecessors, adding a third dimension that prior GLP-1 drugs can't match:
GLP-1 Receptor Activation
Suppresses appetite via the hypothalamus, delays gastric emptying, enhances glucose-dependent insulin secretion, and reduces glucagon when blood sugar is high. The same pathways semaglutide and tirzepatide use.
GIP Receptor Activation
Enhances GLP-1's appetite-suppressing effects, improves insulin sensitivity, and contributes additional metabolic regulation. Tirzepatide also uses this pathway, which is why it outperforms semaglutide.
Glucagon Receptor Activation — The Third Dimension
This is what sets retatrutide apart from everything else:
- Increases energy expenditure — glucagon signals the body to burn more energy, even at rest
- Promotes fat oxidation — signals the liver to break down stored fat for fuel
- Reduces liver fat — Phase 2 showed dramatic liver fat reduction (relevant for MASLD/NAFLD)
- Thermogenic effects — may increase basal metabolic rate
Why Three Is Better Than Two
Semaglutide (GLP-1) primarily reduces how much you eat. Tirzepatide (GLP-1 + GIP) does that better. Retatrutide attacks obesity from both sides — it reduces intake AND increases energy expenditure. This dual mechanism is why weight loss curves in retatrutide trials showed no plateau at 48 weeks, unlike semaglutide and tirzepatide where loss typically plateaus around 6–9 months.
Get exclusive GLP-1 discounts sent to your inbox
Provider discounts, price drops, and new program launches — our list gets them first.
Clinical Trial Evidence
Phase 2 Trial (2023)
Published in the New England Journal of Medicine (2023). 338 adults with obesity (no diabetes), randomized across multiple dose arms, 48 weeks.
Results at 24 weeks:
| Dose | Weight Loss at 24 weeks |
|---|---|
| 1 mg | −7.2% |
| 4 mg | −12.9% |
| 8 mg | −17.3% |
| 12 mg | −17.5% |
| Placebo | −1.6% |
Results at 48 weeks (secondary endpoint):
| Dose | Weight Loss at 48 weeks |
|---|---|
| 8 mg | −22.8% |
| 12 mg | −24.2%(best dose) |
| Placebo | −2.1% |
TRIUMPH-4: First Phase 3 Results (December 2025)
The TRIUMPH clinical program enrolled approximately 5,800 participants across 8 Phase 3 trials. TRIUMPH-4 was the first to report results.
Design: Adults with obesity/overweight AND knee osteoarthritis. Duration: 68 weeks. Doses: 9 mg and 12 mg.
| Metric | 9 mg Dose | 12 mg Dose | Placebo |
|---|---|---|---|
| Avg. weight loss | ~22% | 28.7% | ~2% |
| Avg. pounds lost | — | 71.2 lbs | — |
| Placebo-adjusted loss | — | 26.6% | — |
| OA pain reduction | Significant | 75% | — |
These are the strongest weight loss results ever reported in a Phase 3 obesity trial.
Upcoming TRIUMPH Trial Readouts
Seven more Phase 3 trials are expected to report by end of 2026:
| Trial | Population |
|---|---|
| TRIUMPH-1 | Obesity (primary weight loss trial) — most important for FDA approval |
| TRIUMPH-2 | Obesity with type 2 diabetes |
| TRIUMPH-3 | Obesity maintenance |
| TRIUMPH-5 | Obstructive sleep apnea |
| TRIUMPH-6/7/8 | Additional indications and populations |
TRANSCEND-T2D-1: Type 2 Diabetes Results (March 2026)
On March 19, 2026, Eli Lilly announced top-line results from TRANSCEND-T2D-1 — the first Phase 3 trial of retatrutide specifically in adults with type 2 diabetes (T2D). This is distinct from the TRIUMPH program, which focused on obesity without T2D as its primary criterion.
Trial Design
Phase 3, 40-week, randomized, double-blind, placebo-controlled. 537 participants randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo. Baseline A1C: 7.9%; baseline BMI: 35.8 kg/m².
A1C Reduction at 40 Weeks (Primary Endpoint)
| Dose | A1C Reduction | Weight Loss | Pounds Lost |
|---|---|---|---|
| Retatrutide 4 mg | -1.7% | -11.5% | -24.5 lbs |
| Retatrutide 9 mg | -2.0% | -15.5% | -33.3 lbs |
| Retatrutide 12 mg | -1.9% | -16.8% | -36.6 lbs |
| Placebo | -0.8% | -2.5% | -6.2 lbs |
Cardiovascular Risk Factor Improvements
Eli Lilly reported clinically meaningful improvements across key cardiovascular risk factors:
- Non-HDL cholesterol: reduced significantly vs. placebo
- Triglycerides: reduced significantly vs. placebo
- Systolic blood pressure: improved vs. baseline
Specific numerical values for blood pressure and lipid changes were not included in the March 2026 press release. Full data is expected at the American Diabetes Association Scientific Sessions in June 2026.
Safety Profile in T2D Population
| Side Effect | Rate (retatrutide) | Rate (placebo) |
|---|---|---|
| Nausea | 16.4–26.5% | 3.7% |
| Diarrhea | 18.7–26.3% | 4.5% |
| Vomiting | 15.7–17.6% | 2.2% |
| Dysesthesia | 2.3–4.5% | 0.0% |
| Treatment discontinuation | 2.2–5.1% | 0% |
Notably, dysesthesia rates in the T2D population (2.3-4.5%) were substantially lower than in the obesity-only TRIUMPH-4 trial (8.8-20.9%). Discontinuation rates were also much lower (2.2-5.1% vs 12.2-18.2%). The T2D population may tolerate retatrutide better, or the shorter 40-week duration may account for some of the difference.
What this means for T2D patients
For people with type 2 diabetes who also have obesity, retatrutide offers a meaningful advantage over existing options: A1C reductions of 1.7-2.0% combined with 11.5-16.8% body weight loss in 40 weeks. Current best-in-class agents (tirzepatide, semaglutide) achieve roughly 1.5-2.0% A1C reduction and 8-15% weight loss in T2D populations. Retatrutide's weight loss ceiling appears higher, though it remains unapproved and full peer-reviewed data is pending.
Current Status: Where Does Retatrutide Stand?
As of May 2026:
- ❌NOT FDA-approved — still in Phase 3 trials
- ✅Phase 3 TRIUMPH-4 showed positive results (December 2025)
- ✅TRANSCEND-T2D-1 Phase 3 showed positive A1C and weight loss results in T2D patients (March 2026)
- 🔄Additional Phase 3 trials reporting through end of 2026
- 📋FDA filing likely in 2027 at the earliest
How to access retatrutide today
You cannot get a prescription for retatrutide. It's only available through clinical trial enrollment. Research peptide vendors sell it labeled “for research use only” but this carries significant risk — no quality assurance, no medical oversight, and uncertain purity. We strongly recommend waiting for the approved version.
Side Effects & Safety
New Safety Signal: Dysesthesia
TRIUMPH-4 revealed a new side effect not seen in Phase 2 trials: dysesthesia — abnormal sensation including tingling, burning, or unusual perception of touch.
- • 8.8% of patients on 9 mg
- • 20.9% of patients on 12 mg
- • 0.7% on placebo
Dysesthesia events did not appear to cause treatment discontinuation in the trial, but this signal is being closely monitored across remaining TRIUMPH trials. The cause is under investigation — possibly related to the glucagon component or rapid weight loss.
GI Side Effects
GI side effects are more frequent than semaglutide or tirzepatide, likely reflecting the greater potency of the drug:
| Side Effect | Rate (12 mg) |
|---|---|
| Nausea | 43% |
| Diarrhea | 33% |
| Vomiting | 21% |
| Dysesthesia (abnormal sensation) | 20.9% |
| Treatment discontinuation (12 mg) | 18.2% |
| Treatment discontinuation (9 mg) | 12.2% |
Note: some discontinuations in TRIUMPH-4 were in patients with lower BMI who lost weight faster than expected. Phase 3 safety data is still emerging.
Heart Rate & Cardiovascular Safety
Retatrutide causes a dose-dependent increase in resting heart rate. This is a known consequence of glucagon receptor agonism — the same mechanism that makes retatrutide uniquely powerful for fat burning also has direct effects on cardiac function. Understanding this signal is important for clinical decision-making.
Heart Rate Increase by Dose
| Dose | Avg. HR Increase at Peak (Week 24) |
|---|---|
| 4 mg (low) | +2 to +4 bpm |
| 12 mg (highest) | +~6.7 bpm |
| Semaglutide (reference) | +2 to +3 bpm |
| Tirzepatide (reference) | +2 to +4 bpm |
Why the Increase Happens
Glucagon receptor activation on cardiac cells triggers a cAMP-mediated pathway (via adenylyl cyclase and protein kinase A) that produces both chronotropic effects (faster rate) and inotropic effects (stronger contractions). This pathway is distinct from the sympathetic nervous system, which means beta blockers are likely less effective at controlling retatrutide-induced heart rate elevation than they would be for other causes of tachycardia.
Temporal Pattern: Peak and Partial Recovery
Heart rate elevation is not static during treatment. Available Phase 2 data shows:
- Week 24: Peak heart rate elevation across all dose groups
- Weeks 36-48: Partial decline despite continued dosing — consistent with physiological adaptation
- The increase does not appear to be permanent; it diminishes over time even without dose reduction
Serious Cardiovascular Events
Important caveat: Phase 2 trials excluded participants with significant pre-existing cardiovascular disease. This limits the applicability of these reassuring figures to higher-risk populations. The dedicated cardiovascular outcomes trial, TRIUMPH-Outcomes, is designed to answer whether retatrutide reduces MACE (major adverse cardiovascular events) — results are not expected until 2027-2028.
Net Cardiovascular Picture
The modest heart rate elevation needs to be weighed against substantial cardiovascular risk factor improvements seen across trials:
- Systolic blood pressure: down ~14 mmHg at the 12 mg dose (TRIUMPH-4)
- Non-HDL cholesterol: significantly reduced (TRANSCEND-T2D-1 and Phase 2)
- Triglycerides: significantly reduced across trials
- High-sensitivity CRP: decreased (anti-inflammatory signal)
- Dramatic reduction in liver fat (relevant for cardiometabolic risk)
For most patients without pre-existing cardiac disease, the net cardiometabolic effect of retatrutide appears favorable. A +5-7 bpm heart rate increase is within the range of normal daily variation (standing from sitting raises HR by 10-20 bpm) and is substantially offset by the blood pressure and lipid improvements.
Retatrutide vs. Tirzepatide vs. Semaglutide
Note: comparisons are across separate trials, not head-to-head studies. Individual results will vary.
| Retatrutide | Tirzepatide | Semaglutide | |
|---|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Avg. Weight Loss | 28.7% (Phase 3) | 22.5% | 15% |
| Avg. Pounds Lost | 71.2 lbs | ~56 lbs | ~37 lbs |
| FDA Approved | ❌ Phase 3 | ✅ Yes | ✅ Yes |
| Brand Names | — | Mounjaro, Zepbound | Ozempic, Wegovy |
| Unique Benefit | Fat burning + energy expenditure | Dual pathway | Longest track record |
| Weight Plateau | Not observed at 48 wks | ~6–9 months | ~6 months |
| Liver Fat Reduction | Dramatic | Moderate | Some |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
Frequently Asked Questions
When will retatrutide be available?
The earliest realistic timeline for FDA approval is late 2027 or 2028, assuming the remaining Phase 3 trials are positive and Eli Lilly files promptly. Seven more TRIUMPH trials are expected to report by end of 2026.
Is retatrutide better than tirzepatide?
Based on cross-trial comparisons, retatrutide appears significantly more effective — 28.7% vs. 22.5% weight loss in their respective Phase 3 trials. However, there's no direct head-to-head comparison yet. Retatrutide also has a less established safety profile and a new dysesthesia signal.
What is dysesthesia?
Dysesthesia is an abnormal sensation — tingling, burning, or unusual perception of touch. It was reported in up to 20.9% of patients on the highest dose in TRIUMPH-4, compared to 0.7% on placebo. It's a new signal not seen in Phase 2 and is being closely monitored.
Can I buy retatrutide now?
Retatrutide is not FDA-approved and cannot be prescribed. Research peptide vendors sell it labeled 'for research use only,' but this carries significant risk — no quality assurance, no medical oversight, uncertain purity. We strongly advise against this and recommend waiting for the approved version.
Will retatrutide replace tirzepatide?
Possibly for some patients. Eli Lilly makes both drugs and will likely position retatrutide for patients who need more aggressive weight loss than tirzepatide provides. The two may serve different market segments.
What about the higher side effect rates?
Retatrutide's GI side effects are more significant than semaglutide or tirzepatide — nausea in 43% of patients, vomiting in 21%, and 18.2% discontinuation on the highest dose. The dysesthesia signal is also a new concern. These trade-offs will be carefully weighed as more data emerges.
Stay Updated on Peptide Research
New trial results, FDA updates, and dosing guides — delivered to your inbox.
The Bottom Line
Retatrutide is the most powerful weight loss compound ever tested in large-scale clinical trials. The Phase 3 numbers are remarkable: 28.7% average weight loss, 71.2 lbs lost, with ongoing weight reduction at 68 weeks and no plateau in sight.
But it comes with important caveats. The safety profile needs more scrutiny — the dysesthesia signal is new and concerning at 20.9% incidence, and GI side effect rates are meaningfully higher than its predecessors. It remains years away from FDA approval, and the long-term consequences of such dramatic, rapid weight loss are still being studied.
For now, retatrutide represents the frontier of what's possible with obesity pharmacotherapy. If you need a treatment option today, semaglutide and tirzepatide are your FDA-approved options. If the TRIUMPH program continues to deliver, retatrutide may rewrite the playbook entirely — but that conversation is for 2027 at the earliest.
Maintenance Dosing: After the Escalation Phase
A distinctive feature of retatrutide in Phase 3 data is that weight loss did not plateau during the 68-week escalation period — unlike semaglutide and tirzepatide, which typically plateau around 6–9 months. This raises important questions about long-term maintenance dosing that won't be fully answered until post-approval studies are completed.
Based on Phase 2 and the TRIUMPH-4 data available, the anticipated maintenance framework looks like this: after reaching the target dose (9 mg or 12 mg), patients are expected to remain on that dose indefinitely to maintain weight loss — consistent with the chronic treatment model established by semaglutide. Early discontinuation studies (analogous to STEP 4 for semaglutide) are part of the TRIUMPH program to characterize weight regain patterns after stopping.
One unresolved question is whether patients who achieve very high weight loss (30%+ body weight) can step down to a lower maintenance dose. This is being studied, but no data is available yet. Given that weight loss curves in TRIUMPH-4 had not plateaued at 68 weeks, some researchers have speculated that longer treatment durations may be required to reach a true maintenance equilibrium — and that the eventual maintenance dose may differ from the escalation endpoint.
Key open question
Unlike semaglutide and tirzepatide, which have well-characterized discontinuation data, retatrutide's maintenance and discontinuation profile is still being established through ongoing TRIUMPH trials. Expect more clarity as TRIUMPH-3 (maintenance population) reports in 2026.
Testosterone & Hormonal Effects
Emerging data from retatrutide trials suggests it may have a different hormonal impact profile compared to semaglutide and tirzepatide — driven specifically by its glucagon receptor activity, which the other approved drugs lack.
In men with obesity, significant weight loss from any cause tends to increase testosterone — because adipose tissue converts testosterone to estrogen, and losing fat reduces that conversion. Both semaglutide and tirzepatide show this effect. However, preliminary observations from retatrutide trials suggest the magnitude of testosterone recovery may be larger than weight loss alone would predict, possibly because glucagon receptor activation has independent effects on the hypothalamic-pituitary-gonadal (HPG) axis.
This is still emerging and preliminary — the hormonal data from TRIUMPH trials has not yet been fully published. Glucagon receptor signaling is known to interact with hepatic metabolism and adrenal function, and some researchers hypothesize that the glucagon component of retatrutide may have downstream effects on cortisol and sex hormone binding globulin (SHBG) that differ from pure GLP-1 agonists. For women, the implications for sex hormone levels — including in the context of PCOS, which is frequently comorbid with obesity — are also under investigation.
Availability
Retatrutide is currently in Phase 3 clinical trials and is not yet available through telehealth providers. We will update this guide when it becomes commercially available.
Sources
- 1.Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389(6):514–526.
- 2.Sanyal AJ, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease.” Nat Med. 2024;30:2024–2033.
- 3.Eli Lilly. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” Press release, December 11, 2025.
- 4.Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial.” Lancet. 2023;402(10401):529–544.
- 5.ClinicalTrials.gov. NCT05931367 — TRIUMPH-4.
- 6.“Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2025.
- 7.Eli Lilly. “Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes.” Press release, March 19, 2026. (TRANSCEND-T2D-1 top-line results.)
- 8.ClinicalTrials.gov. NCT05929079 — TRANSCEND-T2D-1 (A Study of Retatrutide in Participants With Type 2 Diabetes Mellitus).
- 9.Jastreboff AM, et al. Retatrutide Phase 2 cardiovascular and heart rate data. N Engl J Med. 2023. (Heart rate subsection: peak +6.7 bpm at week 24, partial decline at weeks 36-48; arrhythmia signals 4-14% vs 2-3% placebo.)